With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.36856-91-4,2-Bromoquinoxaline,as a common compound, the synthetic route is as follows.
A 25-mE round bottom flask equipped with a magneticstirrer, a condenser and a nitrogen inoutlet adapter was charged with 2-bromoquinoxaline (13 mg, 0.063 mmol), boronate ester 6b (25 mg, 0.063 mmol), water/dioxane (1.0 mE/4.0 ml), K2C03 (17 mg, 0.126 mmol). The resulting solution was degassed for 15 mm, then Pd(PPh3)4 (5 mg)was added. The reaction mixture was warmed to 1000 C. and stirred for 1 h. After cooled to room temperature, the reaction mixture was diluted with EtOAc and washed with saturated NaHCO3, brine, dried over Na2SO4. The organic layer was concentrated under reduced pressure and purified on silica gel. Elution with 10% EtOAc/hexanes solvent system afforded the desired compound (15 mg, 60% yield).1H NMR (300 MHz, CDCl3) oe 9.46 (s, 1H), 8.83 (s, 1H), 8.69 (m, 1H), 8.46 (s, 1H), 8.21 (m, 2H), 7.86 (m, 2H), 7.72 (d, J=12.0 Hz, 2H), 7.58 (d, J=12.0 Hz, 2H), 4.05 (s, 3H), 1.42 (s, 9H)., 36856-91-4
As the paragraph descriping shows that 36856-91-4 is playing an increasingly important role.
Reference£º
Patent; Rutgers, The State University of New Jersey; LaVoie, Edmond J.; Parhi, Ajit; Pilch, Daniel S.; Kaul, Malvika; (36 pag.)US9822108; (2017); B2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider